3rd Annual Neuro-Oncology and RNA Therapeutics Symposium

News
MDT.jpg

Event Overview

The Neuro-Oncology and RNA Therapeutics Symposium, organized by Ranjan J. Perera, Ph.D. and George Jallo, M.D., was held on February 20, 2026, at the REB Building at Johns Hopkins All Children's Hospital in St. Petersburg. The symposium convened nationally recognized leaders in brain tumor research, translational neuroscience, and RNA-based therapeutic innovation, highlighting discoveries that are reshaping how we diagnose, treat, and ultimately prevent central nervous system (CNS) malignancies.

A defining moment of the program was the keynote address delivered by Michael D. Taylor, M.D., Ph.D., Professor in the Department of Pediatrics, Section of Hematology-Oncology at Baylor College of Medicine and Director of the Pediatric Brain Tumor Research Program at Texas Children's Hospital. In his presentation, “Prevention Is Better Than Cure,” Dr. Taylor articulated a forward-looking vision for pediatric neuro-oncology—emphasizing prevention-driven science, molecular precision, and the transformative potential of early intervention strategies. The keynote was formally introduced by Dr. George Jallo of Johns Hopkins Medicine, underscoring the collaborative spirit that defined the symposium.

Experts from institutions including Johns Hopkins University, Johns Hopkins Medicine, University of Florida, University of Massachusetts, Children’s Hospital of Philadelphia, and the Perelman School of Medicine at the University of Pennsylvania shared transformative research spanning immuno-oncology, liquid biopsy technologies, RNA therapeutics, molecular targeting, precision radiation strategies, and advanced CNS drug delivery systems.

Through interdisciplinary collaboration and translational discovery, the symposium underscored a shared commitment to accelerating innovative therapies and improving outcomes for pediatric and adult patients alike.

MDT.jpg
MDT.jpg
MDT.jpg
MDT2.jpg
MDT2.jpg
MDT2.jpg
Dr. Henry Brem, M.D. Johns Hopkins University Developing New Therapies for Brain Tumors Dr. Brem discussed innovative therapeutic strategies aimed at advancing new treatment options for brain tumor patients through translational research.
Dr. Henry Brem, M.D. Johns Hopkins University Developing New Therapies for Brain Tumors Dr. Brem discussed innovative therapeutic strategies aimed at advancing new treatment options for brain tumor patients through translational research.
Dr. Henry Brem, M.D. Johns Hopkins University Developing New Therapies for Brain Tumors Dr. Brem discussed innovative therapeutic strategies aimed at advancing new treatment options for brain tumor patients through translational research.
Dr. Henry Brem, M.D. Johns Hopkins University Developing New Therapies for Brain Tumors Dr. Brem discussed innovative therapeutic strategies aimed at advancing new treatment options for brain tumor patients through translational research.
Dr. Henry Brem, M.D. Johns Hopkins University Developing New Therapies for Brain Tumors Dr. Brem discussed innovative therapeutic strategies aimed at advancing new treatment options for brain tumor patients through translational research.
Dr. Henry Brem, M.D. Johns Hopkins University Developing New Therapies for Brain Tumors Dr. Brem discussed innovative therapeutic strategies aimed at advancing new treatment options for brain tumor patients through translational research.
Dr. Henry Brem, M.D. Johns Hopkins University Developing New Therapies for Brain Tumors Dr. Brem discussed innovative therapeutic strategies aimed at advancing new treatment options for brain tumor patients through translational research.
Dr. Henry Brem, M.D. Johns Hopkins University Developing New Therapies for Brain Tumors Dr. Brem discussed innovative therapeutic strategies aimed at advancing new treatment options for brain tumor patients through translational research.
Dr. Henry Brem, M.D. Johns Hopkins University Developing New Therapies for Brain Tumors Dr. Brem discussed innovative therapeutic strategies aimed at advancing new treatment options for brain tumor patients through translational research.
Keynote Speaker: Michael D. Taylor, M.D., Ph.D. Baylor College of Medicine Prevention Is Better Than Cure Dr. Taylor delivered the keynote address, emphasizing prevention-driven strategies and outlining the future landscape of brain tumor research.
Keynote Speaker: Michael D. Taylor, M.D., Ph.D. Baylor College of Medicine Prevention Is Better Than Cure Dr. Taylor delivered the keynote address, emphasizing prevention-driven strategies and outlining the future landscape of brain tumor research.
Keynote Speaker: Michael D. Taylor, M.D., Ph.D. Baylor College of Medicine Prevention Is Better Than Cure Dr. Taylor delivered the keynote address, emphasizing prevention-driven strategies and outlining the future landscape of brain tumor research.
Keynote Speaker: Michael D. Taylor, M.D., Ph.D. Baylor College of Medicine Prevention Is Better Than Cure Dr. Taylor delivered the keynote address, emphasizing prevention-driven strategies and outlining the future landscape of brain tumor research.
Keynote Speaker: Michael D. Taylor, M.D., Ph.D. Baylor College of Medicine Prevention Is Better Than Cure Dr. Taylor delivered the keynote address, emphasizing prevention-driven strategies and outlining the future landscape of brain tumor research.
Keynote Speaker: Michael D. Taylor, M.D., Ph.D. Baylor College of Medicine Prevention Is Better Than Cure Dr. Taylor delivered the keynote address, emphasizing prevention-driven strategies and outlining the future landscape of brain tumor research.
David Sandberg, M.D., FAANS, FACS, FAAP Brain and Heart: The Triumphs and Struggles of a Pediatric Neurosurgeon Dr. Sandberg shared clinical insights and personal reflections from pediatric neurosurgery, highlighting both innovation and resilience in caring for children with complex brain conditions.
David Sandberg, M.D., FAANS, FACS, FAAP Brain and Heart: The Triumphs and Struggles of a Pediatric Neurosurgeon Dr. Sandberg shared clinical insights and personal reflections from pediatric neurosurgery, highlighting both innovation and resilience in caring for children with complex brain conditions.
David Sandberg, M.D., FAANS, FACS, FAAP Brain and Heart: The Triumphs and Struggles of a Pediatric Neurosurgeon Dr. Sandberg shared clinical insights and personal reflections from pediatric neurosurgery, highlighting both innovation and resilience in caring for children with complex brain conditions.
David Sandberg, M.D., FAANS, FACS, FAAP Brain and Heart: The Triumphs and Struggles of a Pediatric Neurosurgeon Dr. Sandberg shared clinical insights and personal reflections from pediatric neurosurgery, highlighting both innovation and resilience in caring for children with complex brain conditions.
David Sandberg, M.D., FAANS, FACS, FAAP Brain and Heart: The Triumphs and Struggles of a Pediatric Neurosurgeon Dr. Sandberg shared clinical insights and personal reflections from pediatric neurosurgery, highlighting both innovation and resilience in caring for children with complex brain conditions.
David Sandberg, M.D., FAANS, FACS, FAAP Brain and Heart: The Triumphs and Struggles of a Pediatric Neurosurgeon Dr. Sandberg shared clinical insights and personal reflections from pediatric neurosurgery, highlighting both innovation and resilience in caring for children with complex brain conditions.
Chetan Bettegowda, M.D., Ph.D. Johns Hopkins Medicine Multi-Analyte Liquid Biopsy Approaches for Brain Tumors Dr. Bettegowda presented advances in noninvasive liquid biopsy technologies for detecting and monitoring brain tumors.
Chetan Bettegowda, M.D., Ph.D. Johns Hopkins Medicine Multi-Analyte Liquid Biopsy Approaches for Brain Tumors Dr. Bettegowda presented advances in noninvasive liquid biopsy technologies for detecting and monitoring brain tumors.
Chetan Bettegowda, M.D., Ph.D. Johns Hopkins Medicine Multi-Analyte Liquid Biopsy Approaches for Brain Tumors Dr. Bettegowda presented advances in noninvasive liquid biopsy technologies for detecting and monitoring brain tumors.
Chetan Bettegowda, M.D., Ph.D. Johns Hopkins Medicine Multi-Analyte Liquid Biopsy Approaches for Brain Tumors Dr. Bettegowda presented advances in noninvasive liquid biopsy technologies for detecting and monitoring brain tumors.
Chetan Bettegowda, M.D., Ph.D. Johns Hopkins Medicine Multi-Analyte Liquid Biopsy Approaches for Brain Tumors Dr. Bettegowda presented advances in noninvasive liquid biopsy technologies for detecting and monitoring brain tumors.
Chetan Bettegowda, M.D., Ph.D. Johns Hopkins Medicine Multi-Analyte Liquid Biopsy Approaches for Brain Tumors Dr. Bettegowda presented advances in noninvasive liquid biopsy technologies for detecting and monitoring brain tumors.
Duane Mitchell, M.D., Ph.D. University of Florida Precision Immuno-Oncology for CNS Malignancies Dr. Mitchell explored precision-based immunotherapeutic strategies designed to improve responses in CNS cancers.
Duane Mitchell, M.D., Ph.D. University of Florida Precision Immuno-Oncology for CNS Malignancies Dr. Mitchell explored precision-based immunotherapeutic strategies designed to improve responses in CNS cancers.
Duane Mitchell, M.D., Ph.D. University of Florida Precision Immuno-Oncology for CNS Malignancies Dr. Mitchell explored precision-based immunotherapeutic strategies designed to improve responses in CNS cancers.
Duane Mitchell, M.D., Ph.D. University of Florida Precision Immuno-Oncology for CNS Malignancies Dr. Mitchell explored precision-based immunotherapeutic strategies designed to improve responses in CNS cancers.
Duane Mitchell, M.D., Ph.D. University of Florida Precision Immuno-Oncology for CNS Malignancies Dr. Mitchell explored precision-based immunotherapeutic strategies designed to improve responses in CNS cancers.
Duane Mitchell, M.D., Ph.D. University of Florida Precision Immuno-Oncology for CNS Malignancies Dr. Mitchell explored precision-based immunotherapeutic strategies designed to improve responses in CNS cancers.
IMG_8446.jpg
IMG_8446.jpg
IMG_8446.jpg
Ranjan J. Perera, Ph.D. Johns Hopkins Medicine / Johns Hopkins All Children’s RNA Therapeutics for Brain Tumors: lncRNA HLX-2-7 and its Host Gene HLX as a Model Dr. Perera highlighted RNA-targeted approaches and emerging therapeutic models in neuro-oncology.
Ranjan J. Perera, Ph.D. Johns Hopkins Medicine / Johns Hopkins All Children’s RNA Therapeutics for Brain Tumors: lncRNA HLX-2-7 and its Host Gene HLX as a Model Dr. Perera highlighted RNA-targeted approaches and emerging therapeutic models in neuro-oncology.
Ranjan J. Perera, Ph.D. Johns Hopkins Medicine / Johns Hopkins All Children’s RNA Therapeutics for Brain Tumors: lncRNA HLX-2-7 and its Host Gene HLX as a Model Dr. Perera highlighted RNA-targeted approaches and emerging therapeutic models in neuro-oncology.
Ranjan J. Perera, Ph.D. Johns Hopkins Medicine / Johns Hopkins All Children’s RNA Therapeutics for Brain Tumors: lncRNA HLX-2-7 and its Host Gene HLX as a Model Dr. Perera highlighted RNA-targeted approaches and emerging therapeutic models in neuro-oncology.
Ranjan J. Perera, Ph.D. Johns Hopkins Medicine / Johns Hopkins All Children’s RNA Therapeutics for Brain Tumors: lncRNA HLX-2-7 and its Host Gene HLX as a Model Dr. Perera highlighted RNA-targeted approaches and emerging therapeutic models in neuro-oncology.
Ranjan J. Perera, Ph.D. Johns Hopkins Medicine / Johns Hopkins All Children’s RNA Therapeutics for Brain Tumors: lncRNA HLX-2-7 and its Host Gene HLX as a Model Dr. Perera highlighted RNA-targeted approaches and emerging therapeutic models in neuro-oncology.
Charles Eberhart, M.D., Ph.D. Johns Hopkins Medicine Targeting miRNA-Mediated Senescence in Pediatric Low-Grade Gliomas Dr. Eberhart discussed microRNA-driven pathways and their potential as therapeutic targets in pediatric brain tumors.
Charles Eberhart, M.D., Ph.D. Johns Hopkins Medicine Targeting miRNA-Mediated Senescence in Pediatric Low-Grade Gliomas Dr. Eberhart discussed microRNA-driven pathways and their potential as therapeutic targets in pediatric brain tumors.
Charles Eberhart, M.D., Ph.D. Johns Hopkins Medicine Targeting miRNA-Mediated Senescence in Pediatric Low-Grade Gliomas Dr. Eberhart discussed microRNA-driven pathways and their potential as therapeutic targets in pediatric brain tumors.
Charles Eberhart, M.D., Ph.D. Johns Hopkins Medicine Targeting miRNA-Mediated Senescence in Pediatric Low-Grade Gliomas Dr. Eberhart discussed microRNA-driven pathways and their potential as therapeutic targets in pediatric brain tumors.
Charles Eberhart, M.D., Ph.D. Johns Hopkins Medicine Targeting miRNA-Mediated Senescence in Pediatric Low-Grade Gliomas Dr. Eberhart discussed microRNA-driven pathways and their potential as therapeutic targets in pediatric brain tumors.
Charles Eberhart, M.D., Ph.D. Johns Hopkins Medicine Targeting miRNA-Mediated Senescence in Pediatric Low-Grade Gliomas Dr. Eberhart discussed microRNA-driven pathways and their potential as therapeutic targets in pediatric brain tumors.
IMG_8455.jpg
IMG_8455.jpg
IMG_8455.jpg
Charles Eberhart, M.D., Ph.D. Johns Hopkins Medicine Targeting miRNA-Mediated Senescence in Pediatric Low-Grade Gliomas Dr. Eberhart discussed microRNA-driven pathways and their potential as therapeutic targets in pediatric brain tumors.
Charles Eberhart, M.D., Ph.D. Johns Hopkins Medicine Targeting miRNA-Mediated Senescence in Pediatric Low-Grade Gliomas Dr. Eberhart discussed microRNA-driven pathways and their potential as therapeutic targets in pediatric brain tumors.
Charles Eberhart, M.D., Ph.D. Johns Hopkins Medicine Targeting miRNA-Mediated Senescence in Pediatric Low-Grade Gliomas Dr. Eberhart discussed microRNA-driven pathways and their potential as therapeutic targets in pediatric brain tumors.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Jeff Coller, Ph.D. Johns Hopkins Medicine / Johns Hopkins University Harnessing mRNA Translation and Stability for the Treatment of Rare Diseases Dr. Coller examined how modulation of mRNA biology can be leveraged to develop innovative treatments.
Andrei Thomas-Tikhonenko, Ph.D. Children’s Hospital of Philadelphia / Perelman School of Medicine at the University of Pennsylvania Leveraging Alternative Splicing Toward New Immunotherapeutics for High-Grade Gliomas Dr. Thomas-Tikhonenko presented novel immunotherapeutic strategies driven by alternative splicing research.
Andrei Thomas-Tikhonenko, Ph.D. Children’s Hospital of Philadelphia / Perelman School of Medicine at the University of Pennsylvania Leveraging Alternative Splicing Toward New Immunotherapeutics for High-Grade Gliomas Dr. Thomas-Tikhonenko presented novel immunotherapeutic strategies driven by alternative splicing research.
Andrei Thomas-Tikhonenko, Ph.D. Children’s Hospital of Philadelphia / Perelman School of Medicine at the University of Pennsylvania Leveraging Alternative Splicing Toward New Immunotherapeutics for High-Grade Gliomas Dr. Thomas-Tikhonenko presented novel immunotherapeutic strategies driven by alternative splicing research.
Andrei Thomas-Tikhonenko, Ph.D. Children’s Hospital of Philadelphia / Perelman School of Medicine at the University of Pennsylvania Leveraging Alternative Splicing Toward New Immunotherapeutics for High-Grade Gliomas Dr. Thomas-Tikhonenko presented novel immunotherapeutic strategies driven by alternative splicing research.
Andrei Thomas-Tikhonenko, Ph.D. Children’s Hospital of Philadelphia / Perelman School of Medicine at the University of Pennsylvania Leveraging Alternative Splicing Toward New Immunotherapeutics for High-Grade Gliomas Dr. Thomas-Tikhonenko presented novel immunotherapeutic strategies driven by alternative splicing research.
Andrei Thomas-Tikhonenko, Ph.D. Children’s Hospital of Philadelphia / Perelman School of Medicine at the University of Pennsylvania Leveraging Alternative Splicing Toward New Immunotherapeutics for High-Grade Gliomas Dr. Thomas-Tikhonenko presented novel immunotherapeutic strategies driven by alternative splicing research.
Rachael Sirianni, Ph.D., MS, MSE, BSE University of Massachusetts Innovation in CNS Drug Delivery: Harnessing Cerebrospinal Fluid Hydrodynamics Dr. Sirianni discussed engineering-based advances designed to optimize therapeutic delivery within the CNS.
Rachael Sirianni, Ph.D., MS, MSE, BSE University of Massachusetts Innovation in CNS Drug Delivery: Harnessing Cerebrospinal Fluid Hydrodynamics Dr. Sirianni discussed engineering-based advances designed to optimize therapeutic delivery within the CNS.
Rachael Sirianni, Ph.D., MS, MSE, BSE University of Massachusetts Innovation in CNS Drug Delivery: Harnessing Cerebrospinal Fluid Hydrodynamics Dr. Sirianni discussed engineering-based advances designed to optimize therapeutic delivery within the CNS.
Rachael Sirianni, Ph.D., MS, MSE, BSE University of Massachusetts Innovation in CNS Drug Delivery: Harnessing Cerebrospinal Fluid Hydrodynamics Dr. Sirianni discussed engineering-based advances designed to optimize therapeutic delivery within the CNS.
Rachael Sirianni, Ph.D., MS, MSE, BSE University of Massachusetts Innovation in CNS Drug Delivery: Harnessing Cerebrospinal Fluid Hydrodynamics Dr. Sirianni discussed engineering-based advances designed to optimize therapeutic delivery within the CNS.
Rachael Sirianni, Ph.D., MS, MSE, BSE University of Massachusetts Innovation in CNS Drug Delivery: Harnessing Cerebrospinal Fluid Hydrodynamics Dr. Sirianni discussed engineering-based advances designed to optimize therapeutic delivery within the CNS.
Rachael Sirianni, Ph.D., MS, MSE, BSE University of Massachusetts Innovation in CNS Drug Delivery: Harnessing Cerebrospinal Fluid Hydrodynamics Dr. Sirianni discussed engineering-based advances designed to optimize therapeutic delivery within the CNS.
Rachael Sirianni, Ph.D., MS, MSE, BSE University of Massachusetts Innovation in CNS Drug Delivery: Harnessing Cerebrospinal Fluid Hydrodynamics Dr. Sirianni discussed engineering-based advances designed to optimize therapeutic delivery within the CNS.
Rachael Sirianni, Ph.D., MS, MSE, BSE University of Massachusetts Innovation in CNS Drug Delivery: Harnessing Cerebrospinal Fluid Hydrodynamics Dr. Sirianni discussed engineering-based advances designed to optimize therapeutic delivery within the CNS.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Elias Sayour, M.D., Ph.D. University of Florida Therapeutic mRNA Cancer Vaccines Dr. Sayour presented cutting-edge research on mRNA vaccine platforms for cancer treatment.
Christopher M. Jackson, M.D. Optimizing Immune Cell Metabolism to Improve Responses to Immunotherapy Dr. Jackson explored how immune cell metabolism can be modulated to enhance immunotherapy effectiveness.
Christopher M. Jackson, M.D. Optimizing Immune Cell Metabolism to Improve Responses to Immunotherapy Dr. Jackson explored how immune cell metabolism can be modulated to enhance immunotherapy effectiveness.
Christopher M. Jackson, M.D. Optimizing Immune Cell Metabolism to Improve Responses to Immunotherapy Dr. Jackson explored how immune cell metabolism can be modulated to enhance immunotherapy effectiveness.
Christopher M. Jackson, M.D. Optimizing Immune Cell Metabolism to Improve Responses to Immunotherapy Dr. Jackson explored how immune cell metabolism can be modulated to enhance immunotherapy effectiveness.
Christopher M. Jackson, M.D. Optimizing Immune Cell Metabolism to Improve Responses to Immunotherapy Dr. Jackson explored how immune cell metabolism can be modulated to enhance immunotherapy effectiveness.
Christopher M. Jackson, M.D. Optimizing Immune Cell Metabolism to Improve Responses to Immunotherapy Dr. Jackson explored how immune cell metabolism can be modulated to enhance immunotherapy effectiveness.
Christopher M. Jackson, M.D. Optimizing Immune Cell Metabolism to Improve Responses to Immunotherapy Dr. Jackson explored how immune cell metabolism can be modulated to enhance immunotherapy effectiveness.
Christopher M. Jackson, M.D. Optimizing Immune Cell Metabolism to Improve Responses to Immunotherapy Dr. Jackson explored how immune cell metabolism can be modulated to enhance immunotherapy effectiveness.
Christopher M. Jackson, M.D. Optimizing Immune Cell Metabolism to Improve Responses to Immunotherapy Dr. Jackson explored how immune cell metabolism can be modulated to enhance immunotherapy effectiveness.
Anita Mahajan, M.D. Director, Johns Hopkins Pediatric Radiation Oncology Research Center at Sibley Memorial Hospital Dr. Mahajan highlighted advancements in pediatric radiation oncology research and precision-based treatment strategies.
Anita Mahajan, M.D. Director, Johns Hopkins Pediatric Radiation Oncology Research Center at Sibley Memorial Hospital Dr. Mahajan highlighted advancements in pediatric radiation oncology research and precision-based treatment strategies.
Anita Mahajan, M.D. Director, Johns Hopkins Pediatric Radiation Oncology Research Center at Sibley Memorial Hospital Dr. Mahajan highlighted advancements in pediatric radiation oncology research and precision-based treatment strategies.
Anita Mahajan, M.D. Director, Johns Hopkins Pediatric Radiation Oncology Research Center at Sibley Memorial Hospital Dr. Mahajan highlighted advancements in pediatric radiation oncology research and precision-based treatment strategies.
Anita Mahajan, M.D. Director, Johns Hopkins Pediatric Radiation Oncology Research Center at Sibley Memorial Hospital Dr. Mahajan highlighted advancements in pediatric radiation oncology research and precision-based treatment strategies.
Anita Mahajan, M.D. Director, Johns Hopkins Pediatric Radiation Oncology Research Center at Sibley Memorial Hospital Dr. Mahajan highlighted advancements in pediatric radiation oncology research and precision-based treatment strategies.